Neuland Labs CEO On Peptide Facility Revenue, 15-20% Growth Guidance & Why Margins Won't Stay At 35%
CNBC-TV18 · 23 Sept 2026 · 1 min
Management interview of Neuland Laboratories Ltd (NEULANDLAB), with 3 key numbers discussed.
- Saharsh Davuluri, Vice Chairman & MD, Neuland Laboratories Ltd
Neuland Laboratories expects its peptide facility to start generating development revenues within the next three quarters, though commercial revenues will follow only post FDA approval. Management targets 15-20% annual growth over the medium term, noting performance may not be uniform every year. Despite reaching 35% EBITDA margins in the previous quarter, the company plans conservatively around a 25% EBITDA margin level, although margins can reach 30% or higher under favorable conditions.